neweramabs - New technologies for monoclonal antibodies

neweramabs GmbH was established in 2014 as a spin-off from the University of Potsdam, Germany, and emerged from a BMBF-funded working group that develops new and efficient technologies for the production of monoclonal antibodies. With these technologies it is possible to produce monoclonal antibodies in half the time and to characterize them for antigen binding at an early stage.

For this purpose, neweramabs GmbH offers special customer-oriented modules that cover the entire production portfolio from epitope analysis to antibody purification. Another business area of new/era/mabs GmbH is in the field of in vitro diagnostics of camelids. Monoclonal mouse anti-camelid (IgG1, 2/3) antibodies are provided and pathogen-specific ELISAs are offered to check the immune status.

The immunization strategy of our partner is based on viruses, more precisely on the hamster polyomavirus. The derived virus particle system is combined with efficient surface-related epitopes. The result is an extremely faster hyperimmunization plan than that of traditional strategies. The individual customer-specific strategies and epitope screening will be discussed in close cooperation. Neweramabs guarantees a surface-related presentation of the target epitope in the viral backbone. This flexibility offers the advantage that a highly effective and antigen-specific immune response is induced on the native target.

Traditional methods of selecting antibody-producing hybridoma cells are tedious, time consuming and costly. Neweramab's solution is a revolutionary technology called selma™. It is based on transgenic myeloma cell lines that express an artificial surface marker. The marker enables antigen-specific antibody to be linked to the secreting hybridoma cell. In addition, flexible screening for desired isotopes and cross-reactivities is possible (desired or undesired). The process of reliable antibody generation and validation is completed in less than 3 months.

For cases or studies where conventional antibodies are not suitable due to their size or the size of the antigen, new/era/mabs offers a clever solution. Our partner provides recombinant antibodies that only consist of the camelid heavy chains. These are not only small and extremely stable, but also show a new spectrum of antigen binding in biodiagnostics. Whether a full-length recombinant antibody molecules or chimeric options is needed, neweramabs is the correct partner.

Search for products by neweramabs

neweramabs products by Product Category”

• 
  All Products